Identification of Nine Genomic Regions of Amplification in Urothelial Carcinoma, Correlation with Stage, and Potential Prognostic and Therapeutic Value

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

High-resolution genomic analysis suggests the absence of recurrent genomic alterations other thanSMARCB1aberrations in atypical teratoid/rhabdoid tumors

(2012) Martin Hasselblatt et al.   GENES CHROMOSOMES & CANCER

Molecular inversion probe analysis detects novel copy number alterations in Ewing sarcoma

(2012) Mona S. Jahromi et al.   Cancer Genetics

High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number

(2011) Benjamin J. Hindson et al.   ANALYTICAL CHEMISTRY

Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma

(2011) Clint E. Johnson et al.   BREAST CANCER RESEARCH AND TREATMENT

Her2 Amplification is Significantly More Frequent in Lymph Node Metastases From Urothelial Bladder Cancer Than in the Primary Tumours

(2011) Achim Fleischmann et al.   EUROPEAN UROLOGY

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP

(2011) Yuan Yuan et al.   Journal of Hematology & Oncology

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

(2011) Yaoting Gui et al.   NATURE GENETICS

A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1

(2011) Gottfrid Sjödahl et al.   PLoS One

Selective Genomic Copy Number Imbalances and Probability of Recurrence in Early-Stage Breast Cancer

(2011) Patricia A. Thompson et al.   PLoS One

Bladder cancer: translating molecular genetic insights into clinical practice

(2010) Liang Cheng et al.   HUMAN PATHOLOGY

FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy

(2010) Lucie C. Kompier et al.   PLoS One

Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium

(2010) Peter J. Goebell et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Cyclin D3 gene amplification in bladder carcinoma in situ

(2010) Antonio Lopez-Beltran et al.   VIRCHOWS ARCHIV

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

(2009) M. Lae et al.   ANNALS OF ONCOLOGY

High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays

(2009) Yuker Wang et al.   BMC Medical Genomics

Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer

(2009) F. M. Platt et al.   CLINICAL CANCER RESEARCH

Nuclear cyclin D1: An oncogenic driver in human cancer

(2009) Jong Kyong Kim et al.   JOURNAL OF CELLULAR PHYSIOLOGY

COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer

(2009) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Comparative Genomic Hybridization Analysis Reveals New Different Subgroups in Early-stage Bladder Tumors

(2009) Esther Prat et al.   UROLOGY

High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies Mouse Double Minute 4 (MDM4) as an Amplification Target Exclusive of MDM2 and TP53

(2008) A. Veerakumarasivam et al.   CLINICAL CANCER RESEARCH

Bladder cancer subtypes defined by genomic alterations

(2008) Margaret A. Knowles   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY

FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression

(2008) Jian-Hua Mao et al.   SCIENCE